Skip to content
BOLUS

Signal from the log

Evvy

40 M$ · Series B · United States

Evvy analyse le microbiote vaginal à domicile et en tire un traitement personnalisé. Elle attaque les erreurs de diagnostic des infections gynécologiques courantes, qu'elle chiffre à plus d'une sur deux en prise en charge classique. Cent mille patientes et trois mille praticiens revendiqués.

Verified

Announced on , logged by the watch of 15 September 2026.

Operation
Funding round
Announced amount
40 M$
Stage
Series B
Country
United States

What the log says

Editorial note, in French

Communiqué ouvert, montant relu et fonds nommés.

The investors

Led by Catalio Capital Management , with US Fertility Innovation Fund , Rethink Impact , Muse Capital , Alumni Ventures , LabCorp Venture Fund , General Catalyst , Left Lane Capital , BBG Ventures , Amboy Street Ventures , Ingeborg , Foreground Capital

Provenance
Source businesswire,pulse2,techcrunch-su,techcrunch-vc,techfundingnews
Logged on 15 September 2026
Description Written in French during the watch run. Based on the headline as relayed by the source, without reading the issuer's press release.
Verification Amounts and fund names were double checked against the issuer's press release or an official filing.
What this status means
Verified The press release was opened: amount double checked, funds named. The article remains to be written.
The rule A signal is never removed from the log. A round set aside stays readable with its reason, because a collection you cannot reread is a collection you cannot correct.

One address, nothing else.

One letter a week, on Fridays: the week's funding rounds, the funds named, the amounts double checked. The list is never sold, one click to unsubscribe. The letter is written in French.

Email confirmation before any subscription. The list is never sold. What Bolus knows about you is written on the privacy page (in French).